Best of ASTRO meeting recognizes most relevant and highly influential research at ASTRO 2017

NASHUA, N.H. and Miami, Fla., (November 9, 2017) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that clinical research comparing use of the company’s Xoft® Electronic Brachytherapy (eBx®) System® to Mohs surgery in the treatment of early-stage non-melanoma skin cancer (NMSC) has been selected “Best of ASTRO 2017.” The “Best of ASTRO” distinction is reserved for the most relevant and highly influential abstracts presented at the 2017 Annual Meeting. The study revealed no statistically significant difference in recurrence of cancer at a mean follow-up of 3.4 years when comparing both forms of treatment. Key findings from the data will be presented at the Best of ASTRO meeting on Nov. 10-11 at the Loews Miami Beach Hotel in Miami, Fla.

“We are honored that ASTRO, the world’s leading radiation oncology society, has recognized the unique, clinical value of our innovative NMSC treatment,” said Ken Ferry, CEO of iCAD. “This acknowledgment further validates the promise of our technology and the significant benefits eBx continues to offer both patients and providers globally.”

In an oral presentation at the 2017 Annual Meeting, Dr. Rakesh Patel, radiation oncologist at Precision Cancer Specialists and lead investigator of the clinical study, presented results of a matched-pair cohort study of 369 early-stage NMSC patients treated with either the Xoft System or Mohs micrographic surgery, known as the gold standard NMSC treatment. Originally published in the peer-reviewed Journal of Contemporary Brachytherapy, the study found that rates of recurrence of cancer in patients treated with eBx or Mohs micrographic surgery were virtually identical. At a mean follow up of 3.4 years, 99.5 percent of eBx patients and 100 percent of Mohs surgery patients remained recurrence free. Further, overall incidence of toxicity was similar in both treatment groups and physician-rated cosmetic outcomes were either “excellent” or “good” in 97.6 percent of eBx-treated lesions, compared to 95.7 percent of Mohs surgery-treated lesions.

“Best of ASTRO recognition empowers physicians with access to meaningful and leading-edge clinical research,” said Dr. Patel. “This important study provides further clinical evidence that eBx is an effective, non-invasive treatment option that achieves similar low rates of recurrence with excellent cosmetic outcomes as compared to Mohs surgery for NMSC patients.”

The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including NMSC, early-stage breast cancer and gynecological cancers. The technology features a miniaturized, low-energy X-ray source that delivers a precise dose of targeted, isotope-free radiation directly to the lesion, reducing the risk of damage to surrounding healthy tissue.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”, “consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, including the 10-K for the year ended December 31, 2016, available on the Investors section of our website at and on the SEC’s website at



For iCAD media inquiries:

Erin Bocherer, 678-294-2258


For iCAD investor relations:

LifeSci Advisors
Jeremy Feffer